PROVENGE (sipuleucel-T) : DENDREON Corp.

ACTIVE CELLULAR IMMUNOTHERAPY)

www.dendreon.com

Dendreon Corporation (Nasdaq: DNDN) announced the presentation of safety data from the integrated analysis of four randomized PROVENGE(R) (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in prostate cancer at the 105th Annual Scientific Meeting of the American Urological Association (AUA) in San Francisco.

"The approval of PROVENGE provides us with an important new, front-line option for men with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer," said Simon Hall, M.D., director of the Barbara and Maurice Deane Prostate Health and Research Center at Mount Sinai Medical Center."

Extended life by average 4.1 months at cost of US$93,000 for 3 dose treatment.

Pres./CEO/Dir. Dr.MITCHELL GOLD MD(Rush,Chicago) Urology resident U.Washington.
Med. Informatics expert.

Sr.V-P.Dr.MARK FROLICH BS(YALE-engineering/economics) MD (HARVARD) past Asst.Prof U.Cal.(San Fran)UROLOGICAL ONCOLOGY

ANNIDIS RHA

ANNIDIS RHA measures RETINAL HEALTH

www.annidis.com see links on ANNIDIS Google.

Invented and made in CANADA.

Developed in OTTAWA at ANNIDIS Health systems Corp. by Dr. BRIAN LEONARD MD(Ottawa 1970) FRCS(C) who did a Fellowship at Philadelphia's WILLS EYE INSTITUTE in RETINOVITREOUS diseases.

Not yet USA approved.